8-K current report · filed Sep 30, 2026

Liquidia Corp (LQDA) 8-K Current Report: September 30, 2026

Item 8.01Item EX-99.1LQDA overview

Short answer

Liquidia Corp (LQDA) filed an 8-K current report with the SEC on September 30, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Liquidia disclosed litigation by United Therapeutics under the Hatch-Waxman Act.

Liquidia Corp 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • Liquidia disclosed litigation by United Therapeutics under the Hatch-Waxman Act
  • Dispute concerns U.S. Patent No. 11,826,327 and Liquidia’s lead product, YUTREPIA inhalation powder
  • Patent litigation creates potential regulatory and commercialization risk for YUTREPIA
  • Exhibit 99.1 contains Liquidia’s press release and additional case details

Item EX-99.1 · Exhibit EX-99.1

  • Claims 1 and 14 of U.S. Patent 11,826,327 found valid and infringed by YUTREPIA
  • Remaining four asserted claims found invalid, narrowing United Therapeutics’ litigation win
  • Court remedy decision pending, with proposals due within one week
  • Potential outcomes range from removing PH-ILD labeling to broader YUTREPIA market restrictions
  • Liquidia plans FDA label supplement and intends to pursue appeals; financial exposure remains unquantified

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Liquidia Corp 8-K filings

Get the next LQDA 8-K as it lands

Follow LQDA for push alerts, or ask the research agent what this filing means.